Tell us about your top U.S. Supreme Court or federal appeals court victory over the past year and how you and your team achieved the win.

[The U.S. Court of Appeals for] the Federal Circuit unanimously affirmed our posttrial success vacating a $200 million jury verdict against our client Gilead Sciences in a patent infringement case with Merck involving Gilead’s blockbuster Sovaldi and Harvoni hepatitis C drugs. After a jury awarded Merck $200 million in damages, amounting to one-tenth of Merck’s $2 billion claim, the district court erased the verdict, finding Merck had forfeited its right to assert its patents against Gilead because of litigation and business misconduct constituting unclean hands. Our strong writ[ing] and oral advocacy convinced the Federal Circuit to affirm both that result and the $14 million legal fee award to Gilead. The Supreme [Court] denied certiorari.